Screener
Adaptive Biotechnologies ADPT Immune Medicine Business — Segment Reporting Other Item Amount
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 / MRD | Three Months Ended March 31, 2026 / Immune Medicine | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / MRD | Three Months Ended March 31, 2025 / Immune Medicine(1) | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Research and development | 9,226 | 13,934 | 23,160 | 9,159 | 14,488 | 23,647 |
| Sales and marketing | 24,742 | * | 24,742 | 21,413 | * | 21,413 |
| General and administrative | 12,519 | * | 12,519 | 9,502 | * | 9,502 |
| Other segment items(2) | — | 5,776 | 5,776 | — | 5,153 | 5,153 |
| Add back: | ||||||
| Items to reconcile net income or net loss to Adjusted EBITDA(3) | 8,776 | 5,569 | 14,345 | 8,127 | 5,813 | 13,940 |
| Adjusted EBITDA(3) | 12,138 | (10,360) | 1,778 | (4,111) | (5,106) | (9,217) |
| Items to reconcile to consolidated net loss: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's immune medicine business — segment reporting other item amount?
- Adaptive Biotechnologies (ADPT) reported immune medicine business — segment reporting other item amount of $5.78M in Q1 2026.
- How has Adaptive Biotechnologies's immune medicine business — segment reporting other item amount changed year-over-year?
- Adaptive Biotechnologies's immune medicine business — segment reporting other item amount increased by 12.1% year-over-year, from $5.15M to $5.78M.
- What is the long-term trend for Adaptive Biotechnologies's immune medicine business — segment reporting other item amount?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's immune medicine business — segment reporting other item amount has grown at a -32.7% compound annual growth rate (CAGR), from $70.02M to $21.38M.
- What does immune medicine business — segment reporting other item amount mean?
- This metric captures miscellaneous expenses or income items specific to the Immune Medicine Business segment that do not fall into standard operating categories. It provides transparency into non-recurring or unique operational costs that impact the segment's overall financial performance.
Ask your AI about Adaptive Biotechnologies's immune medicine business — segment reporting other item amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude